MedTech business service provide leads commercialization of platform oncology medical device.
MAE Group, a New Hampshire-based corporation, leads the commercialization of a thermobrachytherapy oncology medical device, a platform technology, under the MAE Group brand. The project entitled “Project Hope” offers hope to individuals and their families impacted by glioblastoma and other brain cancers. Although MAE Group’s primary focus is GBM, our intent is to expand into other cancerous anatomical sites such as breast cancer.
The commercialization introduces a unique thermobrachytherapy platform technology resulting from the culmination of years of research. Brachytherapy is a form of radiation treatment in which the radioactive materials are sealed inside a seed, pellet, wire, or capsule. The device is then implanted into the body for up to 7 days. The radiation given off by these sources damages the DNA of nearby cancer cells.
Thermobrachytherapy combines the use of core technologies of hyperthermia as a means of enhanced cancer treatment and brachytherapy applied directly to the cancerous area and minimizing healthy tissue toxicity.
MAE Group with the support of an advisory team consisting of scientists from Thomas Jefferson University, received a Phase I National Institutes Health Grant in 2021. The company is currently in the application process for a Phase II NIH grant to move forward with human clinical trials.
A crowd sourcing campaign will increase funding to accelerate the commercialization process.
To learn more about Project Hope and how you can contribute, visit the Project Hope page.
About MAE Group
MAE Group is an enterprise offering services to provide life saving devices to the world. Started in 2013, we now offer a full suite of commercialization services to medical device, in vitro diagnostic device, bioscience and life science companies to bring life-saving products to global markets. MAE Group expertise lies with our in-depth knowledge of regulations and most importantly, interpretation and application of the requirements, to guide any product through the commercialization pathway to successful product launch with strategic and tactical alignment to business plans. In 2021, MAE Group expanded the company’s vision leading the commercialization of a thermobrachytherapy oncology medical device, a platform technology, under the MAE Group brand.
